| POMALIDOMIDE |
Pomalyst® |
Celgene Pty Ltd |
Multiple myeloma |
Jul 2019 |
Not Recommended |
| SAPROPTERIN |
Kuvan® Oral liquid; Kuvan® Tablet (soluble) |
BioMarin Pharmaceutical Australia Pty Ltd |
Hyperphenylalaninaemia (HPA) |
Jul 2019 |
Recommended |
| RIFAXIMIN |
Xifaxan® |
Norgine Pty Ltd |
Prevention of hepatic encephalopathy |
Jul 2019 |
Not Recommended |
| BLINATUMOMAB |
Blincyto® |
Amgen Australia Pty Ltd |
Acute lymphoblastic leukaemia (ALL) |
Jul 2019 |
Recommended |
| APALUTAMIDE |
Erlyand® |
Janssen-Cilag Pty Ltd |
Castration resistant prostate cancer |
Jul 2019 |
Not Recommended |
| CARMELLOSE HYPROMELLOSE |
Evolve® carmellose; Evolve® hypromellose |
Contact Lens Centre Australia Ltd |
Severe dry eye syndrome |
Jul 2019 |
Recommended |
| MUPIROCIN |
Medsurge Mupirocin Nasal Ointment® |
Medsurge Healthcare Pty Ltd |
Staphylococcus aureus infection |
Jul 2019 |
Recommended |
| GALCANEZUMAB |
Emgality® |
Eli Lilly Australia Pty Ltd |
Chronic migraine |
Jul 2019 |
Recommended |
| GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID WITH LOW PHENYLALANINE |
PKU GMPro LQ® |
Nutricia Australia Pty Ltd |
Phenylketonuria (PKU) |
Jul 2019 |
Recommended |
| LEUPRORELIN |
Lerin® |
Sandoz Pty Ltd |
Prostate cancer |
Jul 2019 |
Not Recommended |
| OXYCODONE |
OxyContin® |
Mundipharma Pty Ltd |
Chronic severe disabling pain |
Jul 2019 |
Not Recommended |
| OBETICHOLIC ACID |
Ocaliva® |
Emerge Health Pty Ltd |
Primary biliary cholangitis |
Jul 2019 |
Not Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Non-small cell lung cancer (NSCLC) |
Jul 2019 |
Recommended |
| DURVALUMAB |
Imfinzi® |
AstraZeneca Pty Ltd |
Urothelial cancer |
Jul 2019 |
Not Recommended |
| EVOLOCUMAB |
Repatha® |
Amgen Australia Pty Ltd |
Hypercholesterolaemia |
Jul 2019 |
Deferred |
| DABRAFENIB AND TRAMETINIB |
Tafinlar®; Mekinist® |
Novartis Pharmaceuticals Australia Pty Ltd |
Melanoma |
Jul 2019 |
Recommended |
| ROMOSOZUMAB |
Evenity® |
Amgen Australia Pty Ltd |
Severe osteoporosis |
Jul 2019 |
Not Recommended |
| TRASTUZUMAB |
Herzuma® |
Celltrion Healthcare Australia Pty Ltd |
Breast cancer; Gastric cancer |
Jul 2019 |
Recommended |
| REGORAFENIB |
Stivarga® |
Bayer Australia Ltd |
Hepatocellular carcinoma (HCC) |
Jul 2019 |
Not Recommended |
| FERRIC DERISOMALTOSE |
Monofer® |
Pfizer Australia Pty Ltd |
Iron deficiency anaemia |
Jul 2019 |
Deferred |
| PLITIDEPSIN |
Aplidin® |
Specialised Therapeutics Australia Pty Ltd |
Multiple myeloma |
Jul 2019 |
Not Recommended |
| CINACALCET |
Pharmacor Cinacalcet® |
Pharmacor Pty Ltd |
Chronic kidney disease (CKD) |
Jul 2019 |
Recommended |
| DURVALUMAB |
Imfinzi® |
AstraZeneca Pty Ltd |
Non-small cell lung cancer (NSCLC) |
Jul 2019 |
Not Recommended |
| DENOSUMAB |
Xgeva® |
Amgen Australia Pty Ltd |
Multiple myeloma |
Jul 2019 |
Not Recommended |
| FINGOLIMOD |
Gilenya® |
Novartis Pharmaceuticals Australia Pty Ltd |
Relapsing-remitting multiple sclerosis (RRMS) |
Jul 2019 |
Recommended |
| BUDESONIDE WITH FORMOTEROL |
Symbicort® Turbuhaler® 200/6; Symbicort® Rapihaler® 100/3 |
AstraZeneca Pty Ltd |
Asthma |
Jul 2019 |
Not Recommended |
| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS |
Tylactin Build 20® |
Cortex Health Pty Ltd |
Tyrosinaemia |
Jul 2019 |
Not Applicable |
| ATEZOLIZUMAB |
Tecentriq® |
Roche Products Pty Ltd |
Small cell lung cancer |
Jul 2019 |
Not Recommended |
| AFLIBERCEPT |
Eylea® |
Bayer Australia Ltd |
Subfoveal choroidal neovascularisation |
Jul 2019 |
Recommended |
| LISDEXAMFETAMINE |
Vyvanse® |
Shire Australia Pty Ltd |
Attention defecit hyperactivity disorder (ADHD) |
Jul 2019 |
Recommended |
| LANADELUMAB |
Takhzyro® |
Shire Australia Pty Ltd |
Hereditary angioedema |
Jul 2019 |
Not Recommended |
| OXYCODONE |
OxyNorm® |
Mundipharma Pty Ltd |
Severe disabling pain |
Jul 2019 |
Recommended |
| OCTREOTIDE |
Sandostatin® |
Novartis Pharmaceuticals Australia Pty Ltd |
Non-functional neuroendocrine tumours of midgut or suspected midgut origin |
Jul 2019 |
Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Melanoma |
Jul 2019 |
Deferred |
| SODIUM PHENYLBUTYRATE |
Pheburane® |
Orpharma Pty Ltd |
Urea cycle disorder (UCD) |
Jul 2019 |
Recommended |
| RISANKIZUMAB |
Skyrizi® |
AbbVie Pty Ltd |
Chronic plaque psoriasis |
Jul 2019 |
Recommended |
| DOLUTEGRAVIR WITH LAMIVUDINE |
Dovato® |
ViiV Healthcare Pty Ltd |
Human immunodeficiency virus (HIV) infection |
Jul 2019 |
Deferred |
| RAMUCIRUMAB |
Cyramza® |
Eli Lilly Australia Pty Ltd |
Advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma |
Jul 2019 |
Not Recommended |
| NUSINERSEN |
Spinraza® |
Biogen Australia Pty Ltd |
Spinal muscular atrophy |
Jul 2019 |
Deferred |
| OSIMERTINIB |
Tagrisso® |
AstraZeneca Pty Ltd |
Non-small cell lung cancer (NSCLC) |
Jul 2019 |
Not Recommended |
| TRASTUZUMAB |
Kanjinti® |
Amgen Australia Pty Ltd |
Breast cancer; Gastric cancer |
Jul 2019 |
Recommended |
| DUPILUMAB |
Dupixent® |
Sanofi-aventis Australia Pty Ltd |
Atopic dermatitis |
Jul 2019 |
Not Recommended |
| LUMACAFTOR WITH IVACAFTOR |
Orkambi® |
Vertex Pharmaceuticals (Australia) Pty Ltd |
Cystic fibrosis |
Jul 2019 |
Recommended |
| CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX |
Dysport® |
Ipsen Pty Ltd |
Focal spasticity of the lower limb |
Jul 2019 |
Recommended |
| ENOXAPARIN |
Clexane Forte®; Enoxaparin Winthrop®; Clexane Forte Safety-Lock® |
Sanofi-aventis Australia Pty Ltd |
Deep vein thrombosis (DVT) |
Jul 2019 |
Recommended |
| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS |
TYR Sphere 20® |
Vitaflo Australia Pty Ltd |
Tyrosinaemia |
Jul 2019 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Melanoma |
Jul 2019 |
Not Recommended |
| LENALIDOMIDE |
Revlimid® |
Celgene Pty Ltd |
Multiple myeloma |
Jul 2019 |
Recommended |
| CABOZANTINIB |
Cabometyx® |
Ipsen Pty Ltd |
Hepatocellular carcinoma |
Jul 2019 |
Not Recommended |
| FLUTICASONE FUROATE |
Arnuity Ellipta® |
GlaxoSmithKline Australia Pty Ltd |
Asthma |
Jul 2019 |
Recommended |
| BEZLOTOXUMAB |
Zinplava® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Prevention of recurrent clostridium difficile infection (CDI) |
Jul 2019 |
Not Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS, LOW PHENYLALANINE AND SUPPLEMENTED
WITH DOCOSAHEXAENOIC ACID AND ARACHIDONIC ACID |
PKU Explore® |
Vitaflo Australia Pty Ltd |
Phenylketonuria (PKU) |
Jul 2019 |
Recommended |